Seytri S 250mg/125mg Injection
Marketer
Hauz Pharma Pvt Ltd
Salt Composition
Ceftriaxone (250mg) + Sulbactam (125mg)
Overview Seytri S 250mg/125mg Injection
Seytri S 250mg/125mg Injection, a dual-action medication, combats diverse bacterial infections. Its mechanism prevents microbial proliferation and infection spread. Administration must be strictly under a healthcare provider's guidance; missed doses should be avoided, and the full treatment course completed regardless of symptom improvement. Premature cessation may compromise effectiveness. Common side effects include nausea, vomiting, diarrhea, and dyspepsia; worsening symptoms require immediate medical attention. Seek immediate medical help for allergic reactions (rash, itching, swelling, dyspnea). Inform your doctor about all concurrent medications, including those for pre-existing conditions. Pregnant or lactating individuals should consult their physician before use. Alcohol should be avoided due to potential increased drowsiness. While driving ability is usually unaffected, avoid driving if drowsiness or dizziness occurs. Adequate rest, a nutritious diet, and ample hydration are crucial for optimal recovery. Your doctor may order laboratory tests to monitor treatment efficacy.
Uses of Seytri S 250mg/125mg Injection
Infections caused by bacteria
Major Benefits of Seytri S 250mg/125mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Seytri S 250mg/125mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Seytri S 250mg/125mg Injection:
This medication will be administered by your physician or their designated nursing staff; self-medication is strictly prohibited.
How Seytri S 250mg/125mg Injection works:
Seytri S Injection, containing 250mg Ceftriaxone and 125mg Sulbactam, utilizes a dual-action approach to combat bacterial infections. Ceftriaxone, a cephalosporin antibiotic, disrupts bacterial cell wall synthesis, hindering their ability to reproduce and survive. The addition of Sulbactam, a beta-lactamase inhibitor, counteracts bacterial resistance mechanisms, thereby boosting Ceftriaxone's effectiveness.
SAFETY ADVICE
AlcoholSAFE
There are no reported adverse reactions from using Seytri S 250mg/125mg Injection concurrently with alcohol consumption.
PregnancySAFE IF PRESCRIBED
The injectable medication Seytri S 250mg/125mg is typically deemed safe for pregnant individuals. Preclinical trials in animals revealed minimal or no harmful consequences to fetal development; nevertheless, clinical data from human trials are scarce.
Breast feedingCAUTION
The administration of Seytri S 250mg/125mg Injection to breastfeeding mothers requires careful consideration. Breastfeeding is advised against until maternal treatment concludes and the medication is fully cleared from the mother's system.
DrivingUNSAFE
Administration of Seytri S 250mg/125mg Injection can induce drowsiness, visual disturbances, and dizziness. Operating a vehicle should be avoided if these effects manifest.
KidneyCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Seytri S 250mg/125mg Injection to individuals with renal impairment. Seek medical advice from your physician.
LiverCAUTION
Exercise caution when administering Seytri S 250mg/125mg Injection to individuals with severe hepatic impairment; dosage modification may be necessary. Consult a physician for guidance. Dosage alteration for Seytri S 250mg/125mg Injection is not advised for patients exhibiting mild to moderate liver dysfunction.
What if you forget to take Seytri S 250mg/125mg Injection :
Should you forget a scheduled dose of Seytri S 250mg/125mg Injection, seek medical advice.
Facts to Know About Seytri S 250mg/125mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Antimicrobial Agents |
3,018 People bought this recently